Melanoma
From the Journals
Vaccine regimen boosts immune response in malignant melanoma
Adding a hematopoietic cytokine to a dendritic cell-targeted vaccine improved responses.
Conference Coverage
Mitotic rate makes comeback as melanoma prognosticator
Key insight: the relationship between mitotic rate and melanoma survival is nonlinear.
Conference Coverage
Risk factors for severe immune-related AEs identified
A nationwide cohort study of more than 14,000 patients finds combination immune checkpoint inhibitor therapy, younger age, and a lung cancer...
Conference Coverage
Low threshold to biopsy atypical lesions may ID vulvar melanoma early, experts say
To diagnose one melanoma, doctors may need to biopsy many lesions.
From the Journals
New cancer drugs may have saved more than 1.2 million Americans
Cancer drugs approved between 2000 and 2016 significantly reduced deaths from the most common cancers in the United States.
Conference Coverage
What happened to melanoma care during COVID-19 sequestration
Preliminary evidence indicates delayed diagnosis and treatment measurably worsened outcome indicators.
From the Journals
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.
Conference Coverage
Lower BP and better tumor control with drug combo?
Feature
Are oncologists ready to confront a second wave of COVID-19?
From the Journals
Survey of Mohs surgeons highlights its use in invasive melanoma
“Mohs surgeons who previously treated MIS with MMS may be increasingly doing so and/or expanding their scope of treatment to include invasive...
Conference Coverage
Clinical factors and treatment tied to COVID-19 mortality in cancer patients
Analyses of CCC19 data revealed factors linked to mortality in patients with COVID-19 and cancer.